Thursday, July 3, 2025 7/3/2025

Collagen Signaling in Pancreatic Cancer

Award Number: R01CA281198
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

Collagen Signaling in Pancreatic Cancer - Abstract Pancreatic Ductal Adenocarcinoma (PDA) is the 3rd most common cause of cancer death in the United States. One of the primary pathological features of PDA is the dense network of fibrillar collagens (COLs), including COL1 and COL11, both of which have been shown to be associated with PDA progression. Collagens signal via specific receptors on the surface of PDA cells, of which the Discoidin Domain Receptor 1 (DDR1) is a unique collagen receptor tyrosine kinase (RTK). We have found that ablation of DDR1 inhibits disease progression and metastasis whereas overexpression enhances these processes in mouse models of PDA, suggesting that DDR1 is a major promoter of malignancy. The signaling networks activated by DDR in response to COLs remain elusive. Using an innovative approach to simultaneously map the phospho-catalytic profile of multiple kinases in cells or tissues we discovered that tumor xenografts of PDA cells expressing DDR1 embedded within in a COL1 scaffold display a unique profile of activated kinases, which represent new DDR1-initiated signaling pathways revealing potentially druggable vulnerabilities to target these highly fibrotic tumors. We have also found that COL5 and COL11, fibrillar collagens associated with poor outcome in PDA, actives DDR1 to an almost 20-fold greater level that COL1, its most commonly examine ligand. In this proposal, we will focus on how 1) the COL11/DDR1 signaling axis promotes PDA metastasis in vitro and in vivo 2) how distinct COLs differentially activate DDR1 3) identify druggable vulnerabilities associated with COL5/11- DDR1 signaling to develop for future treatments of these highly fibrotic tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $608,784 )
2025	2025	HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES	426 AUDITORIUM RD	EAST LANSING	MI	48824	INGHAM	USA	Cancer Biology Research	000	2	4/25/2025	NON-COMPETING CONTINUATION	$547,905
2025	2025	HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES	426 AUDITORIUM RD	EAST LANSING	MI	48824	INGHAM	USA	Cancer Biology Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$60,879
														Subtotal = $608,784

Issue Date FY: 2024 ( Subtotal = $630,684 )
2024	2024	HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES	426 AUDITORIUM RD	EAST LANSING	MI	48824	INGHAM	USA	Cancer Biology Research	000	1	4/18/2024	NEW	$630,684
														Subtotal = $630,684

Grand Total All Awards = $1,239,468

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Collagen Signaling in Pancreatic Cancer

Award Number: R01CA281198

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer